Nutritional & Cancer Epidemiology

The Selenium and Bladder cancer Trial

The Selenium and Bladder cancer Trial (SELEBLAT), a phase lll randomized chemoprevention study with Selenium on the recurrence of non-invasive transitional cell carcinoma of the bladder.

The Selenium and Bladder cancer Trial, which opened on the 18th September 2009, was planned to determine the effect of selenium, in addition to standard care, on the prevention of recurrence of non-invasive transitional cell carcinoma of the bladder in 17 Belgian hospitals. SELEBLAT is a phase III randomized, placebo-controlled, academic, double blind trial with selenium yeast (200 μg/day) supplementation during 3 years. All histopathologically confirmed non-muscle-invasive transitional cell carcinoma will be included. Patients below 18 years or stage pT2 and above or other cancer types during the last five years will be excluded. An intention to treat analysis will be performed. Primary endpoint is the recurrence-free interval from date of trial entry to date of recurrence in patients with superficial transitional cell carcinoma of the bladder. Secondary endpoints are the progression-free interval and histological type and size of the recurrent bladder cancer. Since December 2012, 284 patients have been included.

Research group

Prof. Maurice Zeegers
Prof. emerit. Frank Buntinx
Mieke Goossens, MD

Contact

Mieke Goossens, MD
E: mieke.Goossens@med.kuleuven.be